Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Issue 3 (17th August 2005)

• Record Type: Journal Article
• Authors: Da Silva, J A P; Jacobs, J W G; Kirwan, J R; Boers, M; Saag, K G; Inês, L B S; de Koning, E J P; Buttgereit, F; Cutolo, M; Capell, H; Rau, R; Bijlsma, J W J
• Is Part Of: Annals of the rheumatic diseases. Volume 65:Issue 3(2006)
• Page Start: 285
• Page End: 293
• Publication Date: 2005-08-17
• Subjects: BMD, bone mineral density -- COBRA, combination treatment in early rheumatoid arthritis (trial) -- GC, glucocorticoid(s) -- GI, gastrointestinal -- NSAIDs, non-steroidal anti-inflammatory drugs -- RA, rheumatoid arthritis -- SLE, systemic lupus erythematosus; glucocorticoids -- rheumatoid arthritis -- adverse effects; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2005.038638
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Adverse effects of glucocorticoids have been abundantly reported. Published reports on low dose glucocorticoid treatment show that few of the commonly held beliefs about their incidence, prevalence, and impact are supported by clear scientific evidence. Safety data from recent randomised controlled clinical trials of low dose glucocorticoid treatment in RA suggest that adverse effects associated with this drug are modest, and often not statistically different from those of placebo.